Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma

NCT01233375 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
19
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Clovis Oncology, Inc.